Arrowhead Pharmaceuticals Inc (ARWR)
18.54
+0.26
(+1.42%)
USD |
NASDAQ |
Nov 22, 16:00
18.53
-0.01
(-0.05%)
After-Hours: 20:00
Arrowhead Pharmaceuticals Enterprise Value: 1.879B for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | 1.879B |
| November 21, 2024 | 1.846B |
| November 20, 2024 | 1.900B |
| November 19, 2024 | 1.886B |
| November 18, 2024 | 1.938B |
| November 15, 2024 | 1.882B |
| November 14, 2024 | 2.236B |
| November 13, 2024 | 2.263B |
| November 12, 2024 | 2.248B |
| November 11, 2024 | 2.305B |
| November 08, 2024 | 2.295B |
| November 07, 2024 | 2.233B |
| November 06, 2024 | 2.227B |
| November 05, 2024 | 2.131B |
| November 04, 2024 | 2.068B |
| November 01, 2024 | 1.997B |
| October 31, 2024 | 1.965B |
| October 30, 2024 | 2.024B |
| October 29, 2024 | 2.058B |
| October 28, 2024 | 2.083B |
| October 25, 2024 | 2.073B |
| October 24, 2024 | 2.052B |
| October 23, 2024 | 2.050B |
| October 22, 2024 | 2.108B |
| October 21, 2024 | 2.121B |
| Date | Value |
|---|---|
| October 18, 2024 | 2.207B |
| October 17, 2024 | 2.165B |
| October 16, 2024 | 2.197B |
| October 15, 2024 | 2.045B |
| October 14, 2024 | 1.981B |
| October 11, 2024 | 1.866B |
| October 10, 2024 | 1.774B |
| October 09, 2024 | 1.792B |
| October 08, 2024 | 1.814B |
| October 07, 2024 | 1.828B |
| October 04, 2024 | 1.914B |
| October 03, 2024 | 1.917B |
| October 02, 2024 | 1.963B |
| October 01, 2024 | 1.958B |
| September 30, 2024 | 1.982B |
| September 27, 2024 | 2.019B |
| September 26, 2024 | 2.013B |
| September 25, 2024 | 1.988B |
| September 24, 2024 | 2.078B |
| September 23, 2024 | 2.060B |
| September 20, 2024 | 2.160B |
| September 19, 2024 | 2.202B |
| September 18, 2024 | 2.157B |
| September 17, 2024 | 2.062B |
| September 16, 2024 | 2.116B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.587B
Minimum
Mar 18 2020
9.085B
Maximum
Feb 05 2021
4.234B
Average
3.567B
Median
Jan 04 2023
Enterprise Value Benchmarks
| Vaxcyte Inc | 8.855B |
| CEL-SCI Corp | 36.25M |
| AIM ImmunoTech Inc | 8.915M |
| IGC Pharma Inc | 26.16M |
| NovaBay Pharmaceuticals Inc | 2.608M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -170.79M |
| Total Expenses (Quarterly) | 176.14M |
| EPS Diluted (Quarterly) | -1.38 |
| Earnings Yield | -25.13% |
| Normalized Earnings Yield | -14.94 |